Predictors of Pulmonary Hypertension and Right Ventricular Dysfunction in Patients with Hypersensitivity Pneumonitis

Overview

Journal Life (Basel)

Specialty Biology

Date 2023 Jun 28

PMID 37374130

Authors

Natalia V Trushenko

Olga A Suvorova

Galina V Nekludova

Iuliia A Levina

Svetlana Y Chikina

Alexandra M Nikolenko

Natalia A Tsareva

Alexandr V Volkov

Andrey I Yaroshetskiy

Zamira M Merzhoeva

Galiya S Nuralieva

Sergey N Avdeev

Affiliations

Soon will be listed here.

Abstract

Background: Hypersensitivity pneumonitis (HP) is an interstitial lung disease (ILD) that occurs in susceptible individuals in response to various inhaled antigens. The fibrotic phenotype of HP is characterized by disease progression and can lead to pulmonary hypertension (PH). The aim of this study was to estimate the prevalence of PH and to identify predictors of PH in patients with chronic HP.

Methods: We conducted an observational longitudinal study that included 85 patients with an established diagnosis of HP. Clinical examination, quality of life questionnaires, high-resolution computed tomography (HRCT) of the chest, arterial blood gases analyses, six-minute walking test (6-MWT), pulmonary function tests, and echocardiography were performed.

Results: Patients were divided into groups with fibrotic (71.8%) and nonfibrotic phenotype (28.2%). PH was detected in 41 (48.2%) patients. Patients with PH had the predominant fibrotic phenotype of HP, were older, more symptomatic, and had a higher FVC/DLco ratio. The most significant predictors of PH were CT signs of fibrosis, finger clubbing, FVC/DLco, decreased distance, and SpO at the end of 6-MWT, as well as the presence of cardiovascular diseases.

Conclusions: PH is a common condition in patients with chronic HP, especially with the fibrotic phenotype. Early detection of the PH predictors is necessary for the timely diagnosis of this complication of HP.

Citing Articles

Noninvasive diagnostic modalities and prediction models for detecting pulmonary hypertension associated with interstitial lung disease: a narrative review.

Arvanitaki A, Diller G, Gatzoulis M, McCabe C, Price L, Wort S Eur Respir Rev. 2024; 33(174).

PMID: 39384306 PMC: 11462299. DOI: 10.1183/16000617.0092-2024.

Pulmonary hypertension associated with lung diseases.

Shlobin O, Adir Y, Barbera J, Cottin V, Harari S, Jutant E Eur Respir J. 2024; 64(4).

PMID: 39209469 PMC: 11525344. DOI: 10.1183/13993003.01200-2024.

References

McGoon M, Gutterman D, Steen V, Barst R, McCrory D, Fortin T . Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126(1 Suppl):14S-34S. DOI: 10.1378/chest.126.1_suppl.14S. View

Tello K, Axmann J, Ghofrani H, Naeije R, Narcin N, Rieth A . Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol. 2018; 266:229-235. DOI: 10.1016/j.ijcard.2018.01.053. View

Sonti R, Gersten R, Barnett S, Brown A, Nathan S . Multimodal noninvasive prediction of pulmonary hypertension in IPF. Clin Respir J. 2019; 13(9):567-573. DOI: 10.1111/crj.13059. View

Walscher J, Gross B, Morisset J, Johannson K, Vasakova M, Bruhwyler J . Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. Respir Res. 2020; 21(1):12. PMC: 6953142. DOI: 10.1186/s12931-020-1283-8. View

Patel N, Lederer D, Borczuk A, Kawut S . Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007; 132(3):998-1006. DOI: 10.1378/chest.06-3087. View

Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O . Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration. 2012; 85(6):456-63. DOI: 10.1159/000345221. View

Rudski L, Lai W, Afilalo J, Hua L, Handschumacher M, Chandrasekaran K . Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology,.... J Am Soc Echocardiogr. 2010; 23(7):685-713. DOI: 10.1016/j.echo.2010.05.010. View

Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani H, Naeije R . Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circ Cardiovasc Imaging. 2019; 12(9):e009047. PMC: 7099862. DOI: 10.1161/CIRCIMAGING.119.009047. View

Kazimierczyk R, Kazimierczyk E, Knapp M, Sobkowicz B, Malek L, Blaszczak P . Echocardiographic Assessment of Right Ventricular-Arterial Coupling in Predicting Prognosis of Pulmonary Arterial Hypertension Patients. J Clin Med. 2021; 10(13). PMC: 8268071. DOI: 10.3390/jcm10132995. View

10.

Ruocco G, Cekorja B, Rottoli P, Refini R, Pellegrini M, Di Tommaso C . Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model. Respir Med. 2015; 109(3):406-15. DOI: 10.1016/j.rmed.2014.12.011. View

11.

Papadopoulos C, Pitsiou G, Karamitsos T, Karvounis H, Kontakiotis T, Giannakoulas G . Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue Doppler echocardiographic [corrected] study. Eur Respir J. 2007; 31(4):701-6. DOI: 10.1183/09031936.00102107. View

12.

Cooper B, Stocks J, Hall G, Culver B, Steenbruggen I, Carter K . The Global Lung Function Initiative (GLI) Network: bringing the world's respiratory reference values together. Breathe (Sheff). 2017; 13(3):e56-e64. PMC: 5607614. DOI: 10.1183/20734735.012717. View

13.

Alkukhun L, Wang X, Ahmed M, Baumgartner M, Budev M, Dweik R . Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2016; 117:65-72. PMC: 4976395. DOI: 10.1016/j.rmed.2016.06.001. View

14.

Parikh R, Konstantinidis I, OSullivan D, Farber H . Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection. Pulm Circ. 2022; 12(4):e12141. PMC: 9531548. DOI: 10.1002/pul2.12141. View

15.

Raghu G, Remy-Jardin M, Ryerson C, Myers J, Kreuter M, Vasakova M . Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 202(3):e36-e69. PMC: 7397797. DOI: 10.1164/rccm.202005-2032ST. View

16.

Nathan S, Barbera J, Gaine S, Harari S, Martinez F, Olschewski H . Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2018; 53(1). PMC: 6351338. DOI: 10.1183/13993003.01914-2018. View

17.

Huston J, Maron B, French J, Huang S, Thayer T, Farber-Eger E . Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. JAMA Cardiol. 2019; 4(11):1112-1121. PMC: 6751783. DOI: 10.1001/jamacardio.2019.3345. View

18.

Farkas L, Gauldie J, Voelkel N, Kolb M . Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol. 2010; 45(1):1-15. DOI: 10.1165/rcmb.2010-0365TR. View

19.

Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T . Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007; 131(3):650-656. DOI: 10.1378/chest.06-1466. View

20.

Koschel D, Cardoso C, Wiedemann B, Hoffken G, Halank M . Pulmonary hypertension in chronic hypersensitivity pneumonitis. Lung. 2012; 190(3):295-302. DOI: 10.1007/s00408-011-9361-9. View